Simple spit test could predict prostate cancer risk in black, asian, and white men

NCT ID NCT06636526

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new saliva-based DNA test called i4i PRODICT® that estimates a person's future risk of prostate cancer. Researchers want to see if men of Black African/Caribbean, South Asian, and White backgrounds aged 40-55 will take the test and find it acceptable. The test looks at both common and rare genetic changes to classify men as high-risk or population risk, and those at high risk will be offered targeted screening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
i4i PRODICT® test (saliva-based DNA test for genetic risk of prostate cancer)
What this could lead to
If successful, this test could help identify men at high risk for prostate cancer earlier, especially in ethnic groups that are often understudied.
What could go wrong
This is an early study focused on feasibility and uptake, not on proving the test prevents or detects cancer. The test may not accurately predict risk in all groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Royal Marsden Hospital

    RECRUITING

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden Hospital

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.